专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP2858674B1 AN ANTIBODY COMPOSITION FOR PREVENTION OR TREATMENT OF MUTANT HEPATITIS B VIRUS INFECTION 有权
公开(公告)号：EP2858674B1
公开(公告)日：2019-01-30
申请号：EP13817251.5
申请日：2013-07-08
申请人： Green Cross Corporation
发明人： KIM, Se-Ho , HONG, Kwang-Won , SHIN, Wong-won , CHANG, Ki Hwan
IPC分类号： A61K39/395 , A61P31/12 , A61K38/21 , A61K39/42 , A61K45/06

2. 发明授权

EP2726499B1 EPITOPE OF HEPATITIS B VIRUS SURFACE ANTIGEN AND ITS USE 有权
标题翻译：乙型肝炎病毒表面抗原的表位及其应用
公开(公告)号：EP2726499B1
公开(公告)日：2017-11-15
申请号：EP11868565.0
申请日：2011-07-25
申请人： Green Cross Corporation
发明人： KIM, Se-Ho , HONG, Kwang-Won , SHIN, Yong-Won , CHANG, Ki Hwan , KIM, Min-Soo , IM, Jung-Ae
IPC分类号： C07K14/02 , A61K39/29 , A61K39/42 , C07K16/08 , C12N15/36 , C07K17/02 , C12N15/63 , C12N7/01 , C12N15/85 , A61P31/20
CPC分类号： C07K14/005 , A01K67/027 , A01K2207/05 , A01K2227/105 , A01K2267/0337 , A61K39/00 , A61K39/292 , A61K2039/53 , C07K16/082 , C07K2317/34 , C07K2317/76 , C12N7/00 , C12N2730/10122 , C12N2730/10134 , C12N2730/10151

3. 发明公开

EP2726499A1 EPITOPE AND ITS USE OF HEPATITIS B VIRUS SURFACE ANTIGEN 有权
标题翻译： EPITOPEFÜREIN HEPATITIS-B-VIRUS-OBERFLÄCHENENTIGENUND IHR VERWENDUNG
公开(公告)号：EP2726499A1
公开(公告)日：2014-05-07
申请号：EP11868565.0
申请日：2011-07-25
申请人： Green Cross Corporation
发明人： KIM, Se-Ho , HONG, Kwang-Won , SHIN, Yong-Won , CHANG, Ki Hwan , KIM, Min-Soo , IM, Jung-Ae
IPC分类号： C07K14/02 , C07K17/02 , C12N15/36 , C12N15/63 , C12N7/01 , C12N15/85 , A61K39/42 , A61P31/20
CPC分类号： C07K14/005 , A01K67/027 , A01K2207/05 , A01K2227/105 , A01K2267/0337 , A61K39/00 , A61K39/292 , A61K2039/53 , C07K16/082 , C07K2317/34 , C07K2317/76 , C12N7/00 , C12N2730/10122 , C12N2730/10134 , C12N2730/10151
摘要： Disclosed are an epitope specific to hepatitis B virus (HBV) and use thereof. The disclosed epitope is a conservative position on which mutagenesis does not occur and, therefore, a composition including an antibody to the foregoing epitope or a vaccine composition including the epitope has very low possibility of causing degradation of curing efficacy due to HBV mutation, thus being very useful for HBV treatment.
摘要翻译：公开了乙型肝炎病毒（HBV）特异性表位及其用途。所公开的表位是其中不发生诱变的保守位置，因此包含上述表位抗体的组合物或包含该表位的疫苗组合物的组合物具有由于HBV突变导致治愈功效降低的可能性非常低对HBV治疗非常有用。

4. 发明授权

EP2832363B1 EPITOPES OF EPIDERMAL GROWTH FACTOR RECEPTOR SURFACE ANTIGEN AND USE THEREOF 有权
公开(公告)号：EP2832363B1
公开(公告)日：2018-09-19
申请号：EP13769431.1
申请日：2013-03-27
申请人： Green Cross Corporation , Mogam Biotechnology Research Institute
发明人： KIM, Se-Ho , HONG, Kwang-Won , CHANG, Ki Hwan , KIM, Min-Soo , LEE, Mi-Jung , WON, Jong-Hwa , HUR, Min-Kyu , CHO, Hyun-soo , YOO, Ji-Ho
IPC分类号： A61K38/17 , A61K38/16 , A61K39/395 , A61K48/00 , A61P35/00 , A61K39/00
CPC分类号： C07K16/3046 , A61K39/0005 , A61K39/0011 , A61K2039/53 , C07K16/2863 , C07K2317/10 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/567 , C07K2317/76 , C12N15/1037 , G01N33/57492 , G01N2333/71
摘要： The present invention relates to epitopes of the epidermal growth factor receptor (EGFR) and the use thereof. The epitopes provided by the present invention are highly preserved, and located in the domain closely related to binding with an epidermal growth factor (EGF). Therefore, vaccine compositions comprising the epitopes or compositions comprising antibodies to the epitopes may efficiently block a signal transduction caused by binding of EGF and EGRF, and thus can be highly valuably used in treating various diseases such as cancer. An antibody bound to the epitopes of the present invention may efficiently inhibit binding of various EGFR ligands such as not only EGF but also TGF-a, AR, BTC, EPR and HB-EGF, with EGFR, and therefore can be used in treating various diseases resulting from an activation of EGFR caused by binding not only with EGF but also with other EGFR ligands.

5. 发明授权

EP2483309B1 ANTIBODIES SPECIFICALLY BINDING TO THE EPIDERMAL GROWTH FACTOR RECEPTOR 有权
标题翻译：具有特异性结合表皮生长因子受体单克隆抗体
公开(公告)号：EP2483309B1
公开(公告)日：2016-08-17
申请号：EP09850100.0
申请日：2009-11-02
申请人： Green Cross Corporation
发明人： KIM, Se-Ho , CHANG, Ki Hwan , HONG, Kwang-Won , SHIN, Yong-Won , KIM, Min-Soo , LEE, Hae-Won , SHIN, Yong Nam , RYOO, Kyung Hwan , SEO, Dong Hyuck , WON, Jong-Hwa , HUR, Min-Kyu
IPC分类号： C07K16/28
CPC分类号： C07K16/2863 , C07K2317/565

6. 发明公开

EP2483309A1 ANTIBODIES SPECIFICALLY BINDING TO THE EPIDERMAL GROWTH FACTOR RECEPTOR 有权
标题翻译：具有特异性结合表皮生长因子受体单克隆抗体
公开(公告)号：EP2483309A1
公开(公告)日：2012-08-08
申请号：EP09850100.0
申请日：2009-11-02
申请人： Green Cross Corporation
发明人： KIM, Se-Ho , CHANG, Ki Hwan , HONG, Kwang-Won , SHIN, Yong-Won , KIM, Min-Soo , LEE, Hae-Won , SHIN, Yong Nam , RYOO, Kyung Hwan , SEO, Dong Hyuck
IPC分类号： C07K16/28
CPC分类号： C07K16/2863 , C07K2317/565
摘要： Provided are antibodies specifically binding to the epidermal growth factor receptor (EGFR) which are effective for the treatment of EGFR-mediated cancers.

7. 发明公开

EP2858674A1 AN ANTIBODY COMPOSITION FOR PREVENTION OR TREATMENT OF MUTANT HEPATITIS B VIRUS INFECTION 有权
标题翻译：用于预防或治疗突变型乙型肝炎病毒感染的抗体组合物
公开(公告)号：EP2858674A1
公开(公告)日：2015-04-15
申请号：EP13817251.5
申请日：2013-07-08
申请人： Green Cross Corporation
发明人： KIM, Se-Ho , HONG, Kwang-Won , SHIN, Wong-Won , CHANG, Ki Hwan
IPC分类号： A61K39/395 , A61P31/12 , A61K38/21
CPC分类号： C07K16/082 , A61K38/21 , A61K39/42 , A61K45/06 , A61K2039/505 , C07K16/40 , C07K2317/34 , C07K2317/76 , A61K2300/00
摘要： The present invention provides an antibody that binds to the surface antigen (HBsAg) of hepatitis B virus (HBV) to neutralize the hepatitis B virus. The surface antigen-binding site of the antibody was found to play a very important role in viral replication, and when a mutation in the site occurs, viral replication is significantly inhibited, and thus at least HBV virus cannot cause a mutation in the site. In the present invention, it was confirmed by the use of patient-derived virus that the antibody of the present invention binds to either YMDD mutant hepatitis B virus, produced by conventional viral replication inhibitors, or G145R HBsAg mutants to which plasma-derived HBIG (hepatitis B immunoglobulin) does not bind. In addition, the in vivo effect of the antibody of the present invention was examined using chimpanzees which are unique animal models for hepatitis B virus. As a result, it was found that the antibody has the effect of neutralizing even wild-type hepatitis B virus in the in vivo model. Thus, it can be seen that the antibody of the present invention has the ability to bind not only to wild-type hepatitis B virus, but also mutant hepatitis B viruses having a polymerase YMDD mutant and a surface antigen G145R mutation, as well as various mutant viruses derived from patients. Thus, the antibody of the present invention can be effectively used for the prevention or treatment of infections with not only wild-type hepatitis B virus, but also mutant hepatitis B viruses.
摘要翻译：本发明提供了与乙型肝炎病毒（HBV）的表面抗原（HBsAg）结合以中和乙型肝炎病毒的抗体。发现抗体的表面抗原结合位点在病毒复制中起非常重要的作用，并且当该位点发生突变时，病毒复制被显着抑制，因此至少HBV病毒不能引起位点突变。在本发明中，通过使用来自患者的病毒证实，本发明的抗体结合由常规病毒复制抑制剂产生的YMDD突变乙型肝炎病毒或来自血浆来源的HBIG（G145R）的HBsAg突变体乙型肝炎免疫球蛋白）不结合。另外，使用作为乙型肝炎病毒独特动物模型的黑猩猩检查了本发明抗体的体内作用。结果发现该抗体在体内模型中甚至具有中和野生型乙型肝炎病毒的作用。因此，可以看出，本发明的抗体不仅能够结合野生型乙型肝炎病毒，而且能够结合具有聚合酶YMDD突变体和表面抗原G145R突变的突变乙型肝炎病毒以及各种来自患者的突变病毒。因此，本发明的抗体不仅可以有效用于预防或治疗感染野生型乙型肝炎病毒，而且可以用于突变乙型肝炎病毒感染。

8. 发明公开

EP2832363A1 EPITOPES OF EPIDERMAL GROWTH FACTOR RECEPTOR SURFACE ANTIGEN AND USE THEREOF 有权
标题翻译：表皮生长因子受体表面抗原和使用抗原决定基
公开(公告)号：EP2832363A1
公开(公告)日：2015-02-04
申请号：EP13769431.1
申请日：2013-03-27
申请人： Green Cross Corporation , Mogam Biotechnology Research Institute
发明人： KIM, Se-Ho , HONG, Kwang-Won , CHANG, Ki Hwan , KIM, Min-Soo , LEE, Mi-Jung , WON, Jong-Hwa , HUR, Min-Kyu , CHO, Hyun-soo , YOO, Ji-Ho
IPC分类号： A61K38/17 , A61K38/16 , A61K39/395 , A61K48/00 , A61P35/00
CPC分类号： C07K16/3046 , A61K39/0005 , A61K39/0011 , A61K2039/53 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/76 , C12N15/1037
摘要： The present invention relates to epitopes of the epidermal growth factor receptor (EGFR) and the use thereof. The epitopes provided by the present invention are highly preserved, and located in the domain closely related to binding with an epidermal growth factor (EGF). Therefore, vaccine compositions comprising the epitopes or compositions comprising antibodies to the epitopes may efficiently block a signal transduction caused by binding of EGF and EGRF, and thus can be highly valuably used in treating various diseases such as cancer. An antibody bound to the epitopes of the present invention may efficiently inhibit binding of various EGFR ligands such as not only EGF but also TGF-a, AR, BTC, EPR and HB-EGF, with EGFR, and therefore can be used in treating various diseases resulting from an activation of EGFR caused by binding not only with EGF but also with other EGFR ligands.

9. 发明公开

EP2224943A1 USE OF HUMAN ANTIBODY CAPABLE OF NEUTRALIZING HEPATITIS B VIRUS FOR THE PREVENTION OR TREATMENT OF HEPATITIS B VIRUS INFECTION 审中-公开
标题翻译：人类抗体的中和乙型肝炎病毒用于乙型肝炎的预防和治疗
公开(公告)号：EP2224943A1
公开(公告)日：2010-09-08
申请号：EP08854398.8
申请日：2008-11-21
申请人： Green Cross Corporation
发明人： KIM, Se-Ho , HONG, Kwang-Won , SHIN, Yong-Nam , SHIN, Yong-Won , CHANG, Ki-Hwan , RYOO, Kyung-Hwan , CHOI, Jin-Seol , KIM, Pan-Kyung , BONG, Ki-Tae , SEO, Dong-Hyuck , OH, Sun-Jeong
IPC分类号： A61K38/16 , A61K39/395
CPC分类号： A61K38/215 , A61K39/42 , A61K2039/505 , C07K16/082 , C07K2317/56 , A61K2300/00
摘要： The present invention provides a use of a human antibody against a hepatitis B virus (HBV) surface antigen (HBsAg). The antibody exhibits an excellent HBV neutralizing ability, and thus, is useful for the prevention or treatment of the HBV infection or a disease caused thereby.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式